Overview

Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To explore the whole-brain anatomical and functional abnormalities in drug-naive patients with schizophrenia ,drug-naive patients with BD, drug-naive patients with MDD and healthy controls by using a combination of cross-sectional and longitudinal study designs, including a longitudinal study with 8 weeks of drugs treatment. And explore whether there are shared imaging biomarkers between these three common mental disorders.
Phase:
N/A
Details
Lead Sponsor:
Central South University
Treatments:
Antipsychotic Agents
Paroxetine